Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Narazaciclib · ON-123300, HX-301

Small molecule · Inhibitor of NUAK family SNF1-like kinase 1 (ARK5) (NUAK1), cyclin-dependent kinase 4 (CDK4) and cyclin-dependent kinase 6 (CDK6) · developed by Traws Pharma

Phase 1/2 Most advanced trial (none active)
TRAW Developer
2 Registered trials

What is Narazaciclib?

Narazaciclib is an orally bioavailable kinase inhibitor that binds and inhibits NUAK1 (ARK5), CDK4 and CDK6. By blocking CDK4/6-mediated phosphorylation of the retinoblastoma protein in early G1, it causes G1 cell cycle arrest. It is being studied in solid tumors and endometrioid endometrial cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
ON-123300, HX-301
Drug type
Small molecule
Targets
NUAK family SNF1-like kinase 1 (ARK5) (NUAK1), cyclin-dependent kinase 4 (CDK4), cyclin-dependent kinase 6 (CDK6)
Mechanism
Inhibitor of NUAK family SNF1-like kinase 1 (ARK5) (NUAK1), cyclin-dependent kinase 4 (CDK4) and cyclin-dependent kinase 6 (CDK6)
Pathways
Rb phosphorylation, G1-S cell cycle transition, AMPK-related signal transduction
Therapy area
Oncology
Developer
Traws Pharma, Inc. (TRAW)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
QJ8RO3296G

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05705505 Phase 1/2 Endometrioid Endometrial Cancer Unknown TRAW
NCT04739293 Phase 1 Solid Tumors, Adult Unknown TRAW

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Endometrioid Endometrial CancerSolid Tumors, Adult

Other drugs acting on NUAK1 / CDK4 / CDK6

More from Traws Pharma

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the TRAW page.

Follow TRAW, the company behind Narazaciclib

See TRAW's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TRAW catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.